Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nivolumab in stage IIIB/IV or recurrent squamous non-small cell lung cancer
jRCT2080222026Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Pulmonary squamous cell carcinoma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate compared with historical docetaxel threshold. Started Feb 2013; status: completed.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2080222026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222026.